Business Wire

MFA Delivers New Tools for Enterprises to Simplify Their Private Network Deployments

Share

MFA, the industry Alliance supporting private network adoption, today announced that it is launching a new resource center on its website for enterprises to gain access to tools that will aid their 3GPP-based private network deployments and to highlight private networks globally. Enterprises can access these tools to simplify their own private network deployments and to learn about available spectrum options in their region.

“The connectivity requirements of enterprises are becoming more complex, with thousands of devices on a network conducting business-critical applications,” said Mazen Chmaytelli, president, MFA. “MFA is a leading industry resource for enterprises looking to understand the benefits and opportunities of 3GPP-based private networks for their business. Our mission is to make it as easy as possible for enterprises to deploy their own private network in any spectrum, and we are providing the tools and resources to help them facilitate that and achieve their digitalization goals.”

As part of its new private networks resource center, MFA is launching a private network tracker in partnership with industry analyst firm, Mobile Experts. The tracker provides insight into the state of private networks across various industry verticals and enterprises as well as regions where private networks are gaining ground.

“As of the end of June 2022, Mobile Experts estimates that more than 2,800 private LTE and 5G networks have been cumulatively deployed,” said Kyung Mun, principal analyst, Mobile Experts. “We also forecast that the private cellular equipment market will grow 12-15% this year to $1.9B and continue to ramp as the industrial device ecosystem scales. We also see that additional regulators are taking their cue from early actions in Germany, Japan, USA and the UK to make available dedicated private 5G spectrum. MFA will be providing ongoing updates on private network deployments globally so enterprises can learn about trends and best practices.”

New monthly newsletter
Enterprises are encouraged to subscribe to MFA’s new newsletter that will feature a monthly update on private networks deployed globally in a variety of industries, as well as feature new white papers, case studies, and resources. Subscribe at www.mfa-tech.org/newsletter.

Uni5G Technology Blueprints available for enterprises
MFA has also made its Uni5G™ Technology Blueprints publicly available for any enterprise to download. The blueprints leverage 3GPP 5G standards to define profiling and classification requirements for private networks. Enterprises can use the blueprints as a tool with their vendor of choice to let them know which select features their devices need to implement. The initial set of blueprints is based on 3GPP Release 15, and the next set of blueprints based on Release 16 and beyond are under development.

Meet us at Hannover Messe USA
MFA will be presenting at Hannover Messe USA in the Solutions Theater located in Building 1, Level 3.

  • Monday, Sept. 12, 10:30-11:00AM: Practical Tools to Simplify Your Private Network Deployment by Mazen Chmaytelli, MFA President
  • Friday, Sept. 16, 11:15-11:45AM: Deploying a Private 5G Network Doesn’t have to be Rocket Science by Asimakis Kokkos, MFA Technical Specification Group Chair

MFA representatives will also showcase technology solutions and resources in Booth #134661. To schedule a meeting with MFA’s private network experts, contact press@mfa-tech.org.

Resources:

About MFA
MFA is an industry Alliance supporting private network adoption. We provide resources that simplify the path to optimized, reliable and secure private networks in locally licensed, shared, or unlicensed spectrum. MFA enables the ecosystem with its free Uni5G™ Technology Blueprints and its unique global PLMN-ID program. Uni5G, based on 3GPP specifications, identifies the key 5G features needed for enterprises to successfully deploy their own private network. MFA is a 3GPP Market Representation Partner. Learn more at www.mfa-tech.org.

Become an MFA member
Join MFA as a contributor or an adopter member to participate in working groups, receive complimentary access to MFA’s Private Network Identifier packages, and to augment your company’s marketing activities. Learn more at Join | MFA (mfa-tech.org).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact:
Elza Wong
Nereus for MFA
press@mfa-tech.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye